YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Mar 26, 16:00
4405.30
22 (0.5%)
VOLUME 29,978
LIVE
NSE
Mar 26, 15:59
4406.00
25.45 (0.58%)
VOLUME 725,318
News on Dr Reddys Laboratories
Select Year: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Dr Reddy's launches generic hypotensive injection in US

3.01 pm | 30 Dec 2019 |  Source: PTI

The company has launched generic Sodium Nitroprusside injection, 50 mg/2 ml (25 mg/ml) single-dose vial after getting approval from the United States ...

Dr Reddy's launches chronic iron overload treatment tablets in US

1.45 pm | 06 Dec 2019 |  Source: PTI

The company has launched its product, a generic version of Novartis Pharma AG's Exjade tablets for oral suspension, after getting the nod from the...

Dr Reddy's launches cancer treatment injection in US

1.35 pm | 04 Dec 2019 |  Source: PTI

The company has launched Bortezomib for Injection 3.5 mg/vial, approved by the United States Food and Drug Administration (USFDA) via a new drug appli...

Chinese strategy: Dr Reddy's outsources part manufacturing to local parties

3.05 pm | 21 Nov 2019 |  Source: PTI

The company which won the tender to market Olanzapine drug in China, is expected to launch it beginning next year, the official said....

Frequent FDA inspections slow down Indian pharma exports, says GV Prasad

5.23 pm | 18 Nov 2019 |  Source: PTI

According to him, China is a major source of active pharmaceutical ingredients (API) and chemical intermediaries for the global pharmaceutical industr...

Dr Reddy's forays into nutrition segment; launches diabetic-friendly drink

4.20 pm | 14 Nov 2019 |  Source: PTI

It is a first-of-its-kind under Dr Reddy's nutrition portfolio and clinically proven to help manage blood glucose levels among Indian patients, a ...

Dr Reddy's Chinese gamble -- build biz on early mover advantage, recent tender wins

7.17 pm | 04 Nov 2019 |  Source: Moneycontrol.com

Dr Reddy’s is the first Indian company and the second international drug company after Sandoz to be selected and win a supply tender in China under ...

Dr Reddys Labs Standalone September 2019 Net Sales at Rs 3,446.00 crore, up 30.98% Y-o-Y

9.06 am | 04 Nov 2019 |  Source: Moneycontrol.com

NULL...

Dr Reddys Labs Consolidated September 2019 Net Sales at Rs 4,812.80 crore, up 26.07% Y-o-Y

9.02 am | 04 Nov 2019 |  Source: Moneycontrol.com

NULL...

Dr Reddy's Q2 beats estimates, profit doubles to Rs 1,093 crore

12.18 pm | 01 Nov 2019 |  Source: Moneycontrol.com

Dr Reddy's has received tax credit of Rs 326.1 crore during the September quarter against tax expenses of Rs 74.2 crore in the corresponding perio...

Podcast | Hot Stocks: 11,700 level likely to act as resistance for Nifty50

8.35 am | 23 Oct 2019 |  Source: Moneycontrol.com

Traders should use any dip for creating fresh longs as the current trend is likely to remain bullish with Nifty moving towards 11,750-11,800 levels in...

How Cipla's Umang Vohra is trying to invigorate the 84 year old company

7.58 pm | 18 Oct 2019 |  Source: Moneycontrol.com

Vohra’s first two years were spent on cutting the flab, restructuringthe business, rationalising the workforce and improving its productivity....

Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay

3.56 pm | 14 Oct 2019 |  Source: Moneycontrol.com

Net Sales are expected to increase by 9.7 percent Y-o-Y (up 8.4 percent Q-o-Q) to Rs. 4,167.1 crore, according to Emkay....

USFDA issues Establishment Inspection Report for Dr Reddy's Bollaram plant

12.03 pm | 06 Oct 2019 |  Source: Moneycontrol.com

The receipt of EIR indicated closure of the audit of the Bollaram facility...

Ranitidine controversy: Which Indian pharma companies stand to lose?

2.12 pm | 30 Sep 2019 |  Source: Moneycontrol.com

NULL...

Dr Reddy's launches heartburn capsules in US market

5.26 pm | 16 Sep 2019 |  Source: PTI

The company has launched Lansoprazole delayed-release capsules USP in the strength of 15 mg in the US market, as approved by the United States Food an...

Dr Reddys launches generic Emend in US market

7.51 am | 12 Sep 2019 |  Source: PTI

Fosaprepitant is used with other medications to help prevent nausea and vomiting caused by chemotherapy. The launch follows the approval by the US Foo...

Dr Reddy's launches generic Bupropion hydrochloride extended-release tablets in US

1.28 pm | 05 Sep 2019 |  Source: PTI

The company has launched Bupropion hydrochloride extended-release tablets USP (SR), approved by the United States Food and Drug Administration (USFDA)...

Buy Dr. Reddy’s Labs; target of Rs 3360: HDFC Securities

11.23 am | 31 Jul 2019 |  Source: Moneycontrol.com

HDFC Securities is bullish on Dr. Reddy’s Labs has recommended buy rating on the stock with a target price of Rs 3360 in its research report dated J...

Accumulate Dr. Reddy's Laboratories; target of Rs 2997: Prabhudas Lilladher

11.22 am | 31 Jul 2019 |  Source: Moneycontrol.com

Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 2997 in its research report dated July 29,...

1 2 3 4
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.